Wave Life Sciences Inc. Company Profile
NASDAQ: WVEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Wave Life Sciences at a glance
Wave Life Sciences Inc. (NASDAQ: WVE) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Cambridge, MA, Singapore. Wave Life Sciences is led by Dr. Paul B. Bolno M.B.A., M.D. and employs about 317 people. The company's shares have traded publicly since 2015.
At a market capitalization of $697.6 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001631574, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Wave Life Sciences do?
Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders. Its pipeline focuses on obesity (WVE-007), alpha-1 antitrypsin deficiency (AATD) (WVE-006), and PNPLA3 I148M liver disease (WVE-008) programs; and clinical programs for Duchenne muscular dystrophy and Huntington's disease, as well as various preclinical programs utilizing its RNA medicines platform. Wave Life Sciences, Inc. was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Business description based on the company's public filings.
Company information
- Legal name
- Wave Life Sciences Inc.
- Ticker
- NASDAQ: WVE
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Paul B. Bolno M.B.A., M.D.
- Employees
- 317
- Headquarters
- 733 Concord Avenue, Cambridge, MA, Singapore
- Phone
- 617 949 2900
- Website
- wavelifesciences.com
- IPO year
- 2015
- Market cap
- $697.55M
- SEC CIK
- 0001631574
Companies similar to Wave Life Sciences
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| OLMAOlema Pharmaceuticals Inc. | 7.82 | -1.51% | $684.23M | vs WVE |
| GYREGyre Therapeutics Inc. | 6.76 | -3.98% | $716.79M | vs WVE |
| DSGNDesign Therapeutics Inc. | 11.49 | -1.71% | $719.06M | vs WVE |
| COLLCollegium Pharmaceutical Inc. | 22.11 | +0.82% | $719.80M | vs WVE |
| AVTXAvalo Therapeutics Inc. | 13.43 | -1.10% | $720.25M | vs WVE |
| PHARPharming Group N.V. ADS | 9.53 | -1.24% | $674.52M | vs WVE |
| FTHFaeth Therapeutics Inc. | 25.61 | +2.77% | $661.77M | vs WVE |
| VSTMVerastem Inc. | 8.11 | -1.88% | $734.47M | vs WVE |